7. Why the increased interest in African Pharma?
Estimated
IFC (2009)~US$3.8 billion by 2016, others forecast US$ 23 billion by 2020
Local manufacturers account for
Only 25–30%
Population
Current: 1.033 billion
Estimated: 1.3 billion by 2020
11. Increasingly there is purposive engagement to influence policy.
However power and influence over policy and direction:
Global Health Players/Institutions » Continental » Regional »Local institutions!!!
15. Reductions and Increase
Country 2001 2011
Mozambique 14.8% 7.8%
Chad 13.8% 3.3%
DRC 2.8% 10.8%
Achievers
Country 2011
Rwanda 23.8%
Liberia 18.9%
Malawi 18.5%
Zambia 16.0%
Togo 15.4%
Madagascar 15.3%
Nearly There…….
Country 2011
Swaziland 14.9%
Ethiopia 14.6%
Lesotho 14.6%
Djibouti 14.2%
https://www.devex.com/news/health-funding-in-africa-how-close-is-the-au-to-meeting-abuja-targets-81567 accessed 22/04/2014
MNCs see African pharmaceutical markets as a long
term opportunity because of lack of assured public
health financing
If public health funding is resolved then local
manufacturers will face intense competition from
mature market players seeking new avenues for
revenue and profit growth
16. Source: Banda (2013). Finance as a forgotten technological capability for promoting African local pharmaceutical
manufacture in Africa. International Journal of Technology Management and Sustainable Development. 12 (2)
17. Source: Banda (2013). Finance as a forgotten technological capability for promoting African local pharmaceutical
manufacture in Africa. International Journal of Technology Management and Sustainable Development. 12 (2)